The role of pon 1 in determining the long-term prognosis in patients with non-ST-elevation acute coronary syndrome

Objective. The objective of the study was to examine the relationships of the paraoxonase 1 (PON1) level with the development of adverse outcomes in patients with non-ST-elevation acute coronary syndromes (NSTE-ACS) during the year of observation. Materials and Methods. The study included 75 patients with NSTE-ACS. The average age of patients in the sample was 61.1±9.5 years. Study patients comprised 31 (41.3%) men and 44 (58.6%) women. At day 10 of hospitalization, all patients produced PON1 determination in serum. Patients were divided into 2 groups: those with a favorable (n=55) and unfavorable (n=20) outcome [death from cardiovascular causes, unstable angina (UA), myocardial infarction (MI), chronic heart failure (CHF) decompensation, and acute cerebrovascular accident (CVA)]. Results. Reduction in the PON1 levels in serum to less than 4.7 ng/mL increased the risk of hospital readmission for UA during the year of observation in patients with NSTE-ACS by eight times (OR=8.3; 95% CI 1.7-42.1; p=0.002) and the risk of common adverse cardiovascular events by four times (OR=4.2; 95% CI 1.3-13.4; p=0.009). In this study, we investigated potential adverse prognostic role of PON1 in patients with NSTE-ACS. Data demonstrated that reduction in the PON1 blood levels to less than 4.7 ng/mL increased the one-year risk of an adverse outcome in patients with NSTE-ACS by four times.